Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

BACKGROUND: Uterine serous carcinomas (USCs) are an aggressive form of uterine cancer that may rely on HER2/neu amplification as a driver of proliferation. The objective of this paper is to assess the sensitivity of USC cell lines with and without HER2/neu gene amplification to afatinib, an irrevers...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwab, C L, Bellone, S, English, D P, Roque, D M, Lopez, S, Cocco, E, Nicoletti, R, Bortolomai, I, Bonazzoli, E, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Santin, A D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453741/
https://www.ncbi.nlm.nih.gov/pubmed/25268372
http://dx.doi.org/10.1038/bjc.2014.519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453741/
https://www.ncbi.nlm.nih.gov/pubmed/25268372
http://dx.doi.org/10.1038/bjc.2014.519

Ejemplares similares